AIM
LRMR icon

Alambic Investment Management’s Larimar Therapeutics LRMR Stock Holding History

Alambic Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,600
Closed -$37K – 332
2019
Q2 		$37K Sell
2,600
-292
-10% -$7.78K 0.02% 291
2019
Q1 		$95K Buy
+2,892
New +$148K 0.04% 321

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Alambic Investment Management's LRMR Position: Q3 2019 in Review

Alambic Investment Management sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 2,600 shares — an estimated $37K sold.

Alambic Investment Management first reported a position in LRMR in Q1 2019 and held it in 2 quarters. The position peaked at $95K in Q1 2019. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

  • Alambic Investment Management reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Alambic Investment Management sold 2,600 Larimar Therapeutics shares in Q3 2019, an estimated $37K.
  • Alambic Investment Management first reported a position in Larimar Therapeutics in Q1 2019 and held it in 2 quarters.
  • Alambic Investment Management's Larimar Therapeutics position peaked at $95K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on Alambic Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.